COMPARING ANTIPROLIFERATIVE AND PROAPOPTOTIC EFFECTS OF THE PAN-DEACETYLASE INHIBITOR PANOBINOSTAT WITH DOXORUBICIN ON HEPG2 HEPATOCELLULAR CARCINOMA CELL LINE

Authors

Neimat Abd Elhakam Elmetwaly, *Assistant lecturer of clinical pharmacology, Mansoura faculty of medicine
Mona Younis Youssef, *Assistant lecturer of clinical pharmacology, Mansoura faculty of medicine
Amal Abd Elhameed Mohammad, Lecturer of pathology, Mansoura faculty of medicine
Karawan Mohammad Abd Elrahman, Lecturer of pathology, Mansoura faculty of medicine
Farida Hanem Mohammad Ali Elbanna, professor of clinical pharmacology, Mansoura faculty of medicine

Article Type

Original Study

Abstract

Panobinostat is a new histone deacetylaseinhibitor approved fortreatmentof advanced multiple myeloma.In this study we compare itseffectswith doxorubicin which is alreadyused for trans-arterial chemoembolizationof hepatocellular carcinoma. Methods: anti-proliferativeand pro-apoptotic effects of panobinostatand doxorubicin are tested bymeasuringcell viability, P53, pd1 expressionand cell cycle analysis inHepG2cells cultured in suitable mediaand incubated with both drugs for24hours. Results:Panobinostat wasfoundto highly significantly induce apoptosis via increasing expressionof both P53 and pd1 and decreasecell viability and mitosis more thandoxorubicin. Conclusion: These resultssuggest that panobinostat maybea potent alternative to doxorubicinfortreatment of hepatocellular carcinoma.

Recommended Citation

Elhakam Elmetwaly, Neimat Abd; Younis Youssef, Mona; Abd Elhameed Mohammad, Amal; Mohammad Abd Elrahman, Karawan; and Hanem Mohammad Ali Elbanna, Farida (2015) "COMPARING ANTIPROLIFERATIVE AND PROAPOPTOTIC EFFECTS OF THE PAN-DEACETYLASE INHIBITOR PANOBINOSTAT WITH DOXORUBICIN ON HEPG2 HEPATOCELLULAR CARCINOMA CELL LINE," Mansoura Medical Journal: Vol. 44 : Iss. 1 , Article 6.
Available at: https://doi.org/10.21608/mjmu.2015.124268

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.